Table 1.
The epitopes employed here
| Epitope Target | Epitope Sequence | Previously Reporteda Kd(nM) |
Observed Kd (nM) |
Sensor Gainb |
|---|---|---|---|---|
| FLAG | DYKDDDDKGG | 3 nM | 3.0 ± 0.5 nM | −45% |
| HIV gp41 (4B3) | LWGCSGKLVCTT | Not reported | 7 ± 2nM | −45 ± 4% |
| HIV gp41 (2F5) | ELLELDKWASLWNC | 0.77 nM | 1.7 ± 0.2 nM | −83 ± 4% |
| HIV gp41 (4E10) | CSLWNWFNITNWLWYIKC | 20.2 nM | N/A | N/A |
| NWFDITNWLWYIKKKK | 20 nM | 1.6 ± 0.2 nM | −70 ± 6% | |
| HIV p17 (32/1.24.89) |
GKIRLRPG | Not reported | N/A | N/A |
| EKIRLR | 200 pM | 2 ± 1 nM | −50 ± 6% | |
| HIV p24 (M01) | GATPQDLNTML | Not reported | 5 ± 1 nM | −47 ± 6% |
a
Taken from the following references: FLAG(26,27), 2F5(28,29), 4E10(30), p17(31,33), 4B3(32), M01(34).
b
Relative signal change observed at saturating (40 nM) antibody concentration. Confidence intervals represent the standard deviation of at least three independently fabricated sensors.